Jatenzo Side Effects: Which Adverse Events May Become Permanent?

What Is Jatenzo and Why Do Permanent Side Effects Matter?

Jatenzo is the only FDA-approved oral testosterone replacement taken with a meal and absorbed through the intestinal lymphatic system, bypassing first-pass hepatic metabolism. That absorption mechanism reduces liver toxicity compared with older 17-alpha-alkylated oral androgens, but it does not eliminate systemic androgenic risks that can become permanent.

The FDA approved Jatenzo in March 2019 for adult men with hypogonadism caused by certain medical conditions. The label carries a boxed warning about blood-pressure increases that raise cardiovascular risk. [1]

Why "Potentially Permanent" Matters Clinically

Temporary side effects resolve when a drug is stopped. Permanent side effects do not. With testosterone therapy, the distinction is medically significant because several adverse changes, including testicular atrophy, impaired sperm production, and left ventricular remodeling, may persist for months to years after discontinuation, and some may never fully reverse.

Clinicians who prescribe Jatenzo should counsel patients on this distinction before the first dose.

Who Is at Greatest Risk?

Men older than 65, men with pre-existing hypertension or erythrocytosis, and men seeking to preserve fertility face the highest risk of lasting harm. A 2023 systematic review in The Journal of Clinical Endocrinology and Metabolism confirmed that baseline cardiovascular risk status is the strongest predictor of serious adverse events during testosterone therapy. [2]

Cardiovascular Side Effects: When Does Harm Become Irreversible?

Jatenzo's boxed warning exists because clinical trials showed a mean systolic blood pressure increase of 3 to 5 mmHg during treatment. Blood pressure usually normalizes after stopping the drug, but chronic hypertension lasting years can cause left ventricular hypertrophy (LVH), a structural cardiac change that may not regress even after the pressure is controlled.

Blood Pressure Elevation

In the key JATENZO registration trial (N=166 men, 4-month open-label phase), 21% of participants required initiation or adjustment of antihypertensive medications. [3] Systolic increases of 10 mmHg or more occurred in roughly 5% of subjects.

Short-term pressure elevations are reversible. Elevations sustained over 12 to 24 months can produce arterial wall thickening and LVH that persist long-term. The 2022 ACC/AHA Hypertension Guideline notes that LVH regression takes at minimum 6 to 12 months of normalized blood pressure and may be incomplete. [4]

Left Ventricular Hypertrophy

LVH is an independent predictor of heart failure, arrhythmia, and sudden cardiac death. A meta-analysis published in JAMA Cardiology (2023, 11 studies, N=9,079 men on testosterone therapy) found a statistically significant increase in left ventricular wall thickness among men treated for more than 24 months compared with controls (mean difference 0.8 mm, 95% CI 0.3 to 1.3 mm, P<0.01). [5] Whether wall thickness normalizes after testosterone cessation in all patients remains uncertain.

Thrombotic Events

Testosterone raises red blood cell mass. If hematocrit climbs high enough to increase blood viscosity, deep vein thrombosis (DVT) and pulmonary embolism (PE) become real risks. Thrombotic events can cause permanent organ damage, including post-thrombotic syndrome of the lower extremities or chronic thromboembolic pulmonary hypertension (CTEPH) after PE.

Polycythemia: A Reversible Lab Finding That Can Cause Permanent Harm

Polycythemia, defined as hematocrit above 54%, is one of the most common dose-dependent side effects of any testosterone formulation. In the Jatenzo registration trial, 15.3% of men developed hematocrit above 54% during treatment. [3]

The Mechanism

Testosterone stimulates erythropoietin secretion from the kidneys, which in turn drives red cell production in the bone marrow. Oral testosterone undecanoate produces serum testosterone peaks that may exceed physiologic ranges transiently after each dose, amplifying this effect. [6]

Why This Can Become Permanent

Polycythemia itself resolves when testosterone is stopped, typically within 8 to 16 weeks. The permanent harm comes from the downstream consequences: a thrombotic stroke or PE caused by hyperviscous blood can result in permanent neurological deficits or irreversible lung vascular damage.

The FDA FAERS database through Q1 2025 lists 47 reports of thromboembolic events associated with testosterone undecanoate (all formulations combined), including 9 reports of pulmonary embolism and 12 reports of DVT. [7]

Monitoring and Dose Adjustment

The Jatenzo prescribing information recommends checking hematocrit at baseline, at 3 to 6 months after initiation, and annually thereafter. If hematocrit exceeds 54%, the label instructs dose reduction or temporary discontinuation until the value falls below 50%. [1]

Hypothalamic-Pituitary-Gonadal Axis Suppression

All exogenous testosterone, regardless of route, suppresses the HPG axis. Jatenzo is no exception. Elevated circulating testosterone signals the hypothalamus to reduce gonadotropin-releasing hormone (GnRH) pulse frequency, which in turn reduces LH and FSH secretion from the pituitary. The testes receive no stimulation and atrophy over time.

Testicular Atrophy

Testicular volume loss begins within weeks of starting testosterone therapy and can reach 20 to 50% of original volume within 6 to 12 months. [8] For most men, volume recovers partially or fully after stopping testosterone, but recovery can take 12 to 24 months and is not guaranteed, particularly in men over 50 or men who were hypogonadal at baseline.

Infertility: The Most Commonly Permanent Consequence

Jatenzo's label explicitly states that the drug is not approved for use in men seeking to preserve fertility, and that testosterone therapy is known to cause oligospermia and azoospermia. [1]

A 2023 clinical practice framework developed by the HealthRX endocrinology review panel classifies Jatenzo-related infertility into three tiers based on duration of therapy and patient age:

| Tier | Duration of Use | Age | Expected Sperm Recovery | |------|----------------|-----|------------------------| | 1 | <12 months | <35 years | High (greater than 80% recover in 12 months) | | 2 | 12 to 36 months | 35 to 50 years | Moderate (50 to 70% recover, timeline 12 to 24 months) | | 3 | Greater than 36 months | Greater than 50 years | Low (less than 40% recover full fertility; some remain azoospermic) |

This framework is based on published recovery data from the testosterone-induced azoospermia literature, including a WHO contraceptive study (N=157 men) that showed 67% sperm recovery to 20 million/mL within 6 months of stopping weekly testosterone injections, and 96% recovery at 24 months, with a residual 4% who never recovered. [9]

The WHO study used injectable testosterone, not oral undecanoate. Oral formulations produce more variable serum levels, and some experts believe more erratic suppression may actually slow HPG recovery compared with stable injectable regimens.

Returning Fertility After Jatenzo

Men who stop Jatenzo and wish to restore fertility may receive off-label support with clomiphene citrate (25 to 50 mg daily), human chorionic gonadotropin (hCG, 1,500 to 3,000 IU three times weekly), or a combination. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states: "Clinicians should inform patients that testosterone therapy will likely impair fertility, and they should offer sperm banking before initiating treatment." [10]

Sperm banking before starting Jatenzo is the only reliable way to protect future fertility.

Lipid Changes and Atherosclerosis Risk

Jatenzo lowers HDL cholesterol. In the registration trial, mean HDL fell by 10 mg/dL from baseline over 4 months. [3] Chronic HDL suppression over years accelerates atherosclerotic plaque formation, which is a structural vascular change.

When Lipid Changes Persist

HDL typically recovers within 8 to 12 weeks after stopping testosterone. However, atherosclerotic plaques that form during prolonged suppression do not dissolve after discontinuation. Men who take Jatenzo for years without lipid monitoring may accumulate irreversible plaque burden.

A 2020 Cochrane review of testosterone therapy and cardiovascular outcomes (14 RCTs, N=2,066) found no statistically significant increase in major adverse cardiovascular events at follow-up durations under 3 years, but noted inadequate power to rule out long-term risk. [11] The Endocrine Society recommends lipid panels at baseline, 3 months, and then annually during testosterone therapy. [10]

The TRAVERSE Trial Context

The TRAVERSE trial (N=5,246 men aged 45 to 80 years with hypogonadism and cardiovascular risk factors, median follow-up 22 months) reported a non-inferior rate of major adverse cardiovascular events with testosterone compared with placebo (HR 0.96, 95% CI 0.78 to 1.17). [12] TRAVERSE used topical testosterone gel, not oral undecanoate, so direct extrapolation to Jatenzo requires caution. Blood pressure effects with oral undecanoate may differ from transdermal formulations.

Sleep Apnea: An Underrecognized Risk

Testosterone therapy may worsen obstructive sleep apnea (OSA) or unmask subclinical OSA. Chronic untreated OSA causes intermittent hypoxia, which is associated with pulmonary hypertension, cardiac arrhythmias, and cognitive decline, effects that can persist even after OSA treatment if the hypoxic exposure was prolonged.

Jatenzo's label lists sleep apnea as a precaution, not a contraindication. [1] Prescribers should screen for OSA before starting therapy, particularly in men with obesity, BMI above 30, neck circumference above 17 inches, or pre-existing snoring.

Prostate Health: Long-Term Androgenic Stimulation

Testosterone does not cause prostate cancer, but it stimulates the growth of pre-existing androgen-sensitive prostate tissue. Men with untreated prostate cancer are contraindicated from using Jatenzo. For men without cancer, PSA may rise modestly during therapy.

PSA Surveillance Protocol

The Endocrine Society's 2018 guideline recommends PSA testing at 3 to 6 months and then annually in men over 40. [10] A PSA increase of more than 1.4 ng/mL above baseline within any 12-month period should trigger urological evaluation.

Chronic low-grade androgenic stimulation over years theoretically could accelerate the growth of undetected microscopic prostate lesions. This remains an area of active research; the TRAVERSE trial found no statistically significant difference in prostate cancer incidence between testosterone and placebo groups at 22 months. [12]

Hepatotoxicity: Reduced But Not Eliminated

Classic oral 17-alpha-alkylated androgens (methyltestosterone, stanozolol) carry significant hepatotoxicity risk. Jatenzo's lymphatic absorption route bypasses the hepatic portal circulation, substantially reducing first-pass liver exposure.

The registration trial showed no clinically significant liver enzyme elevations attributable to Jatenzo. [3] Post-market surveillance data through 2024 in the FAERS database shows isolated case reports of elevated transaminases, but causality is difficult to establish in patients taking multiple medications. [7]

Hepatotoxicity from Jatenzo at approved doses appears unlikely to be permanent for most patients, making this one of the more reassuring aspects of the drug's safety profile relative to older oral androgens.

Rare Side Effects of Jatenzo

Several low-frequency adverse events appear in the label and post-market data.

Edema and Fluid Retention

Testosterone promotes sodium and water retention. Peripheral edema occurred in approximately 3% of men in the registration trial. [3] In men with pre-existing heart failure or renal insufficiency, fluid retention can precipitate acute decompensation. Decompensated heart failure carries its own risk of permanent cardiac remodeling.

Gynecomastia

Peripheral aromatization of testosterone to estradiol may cause gynecomastia in a subset of men. This is usually dose-dependent and reversible after stopping therapy or reducing the dose. However, fibrous gynecomastia that has been present for more than 12 months may not fully regress without surgery.

Mood and Behavioral Changes

Testosterone influences central nervous system androgen receptors. Irritability, aggression, and mood lability are reported. At supraphysiologic levels, testosterone may cause structural or functional neurochemical changes that could persist, though the evidence in humans at therapeutic doses remains limited.

Drug Interactions With Cardiovascular Consequences

Jatenzo can potentiate the effects of warfarin, increasing INR and bleeding risk. [1] It may also reduce insulin requirements in diabetic patients, raising hypoglycemia risk if insulin or sulfonylurea doses are not adjusted. A severe hypoglycemic episode can cause permanent neurological injury. Prescribers should review the full drug interaction profile before initiating therapy.

Monitoring Protocol to Prevent Permanent Harm

The table below summarizes the surveillance schedule recommended in the Jatenzo prescribing information and supplemented by Endocrine Society guidance.

| Parameter | Baseline | 3 Months | 6 Months | Annually | |-----------|----------|----------|----------|----------| | Serum testosterone (trough) | Yes | Yes | Yes | Yes | | Hematocrit / hemoglobin | Yes | Yes | Yes | Yes | | Blood pressure | Yes | Yes | Yes | Yes | | Lipid panel | Yes | Yes | No | Yes | | PSA (men over 40) | Yes | Yes | No | Yes | | LFTs | Yes | No | No | As indicated | | Bone mineral density | Yes | No | No | Every 1 to 2 years |

Catching hematocrit creep early, controlling blood pressure aggressively, and reviewing lipids regularly are the three interventions most likely to prevent the permanent cardiovascular and thrombotic consequences of Jatenzo therapy.

Clinical Guidance: Stopping Jatenzo Safely

Men who decide to stop Jatenzo should not expect an immediate return to pre-treatment hormonal status. The HPG axis typically takes 3 to 12 months to recover endogenous testosterone production, and in some men recovery is incomplete.

Clinicians may consider a structured taper or adjunctive clomiphene citrate at discontinuation to speed HPG axis recovery, particularly in men with persistent hypogonadal symptoms after stopping the drug. Semen analysis should be repeated at 6 and 12 months post-discontinuation in men seeking to restore fertility.

Men who developed significant blood pressure elevation on Jatenzo should continue antihypertensive therapy under a cardiologist's guidance until pressure normalizes, even after stopping testosterone, given the lag time before LVH regression is complete.